BioMarin Pharmaceutical Inc.: Morgan Stanley cuts target price to $103 from $119
BMRN•Morgan Stanley cut its target price for BioMarin Pharmaceutical Inc. to $103 from $119.
Related News
EMA's CHMP recommends indication extensions for Bexsero and Talzenna
PFE•
Morgan Stanley raises Neurocrine Biosciences target price to $191 from $185
NBIX•
Organigram agrees to acquire Aurora Cannabis
OGI•
Lloyds finds 45% of internationally trading UK firms plan expansion into new markets
LYG•
Abercrombie & Fitch Co.: Morgan Stanley raises target price to $150 from $134
ANF•